EEF1A2 and neoplasm: Several monoclonal antibodies exist to target both STn and SLeA antigens 151, 152, which may be used to induce antibody-dependent cellular cytotoxicity (ADCC) 153, 154, a mechanism by which many clinically available therapeutic antibodies promote anti-tumor effects 155, or block relevant oncogenic receptors 20 (Figure 5).